The compounds researchers look up most often in the peptide library — from BPC-157 and TB-500 to semaglutide, ipamorelin, and epithalon. Each profile links to our cited roundup when one exists.
BPC-157 is a synthetic pentadecapeptide sequence derived from gastric-juice protein fragments. It is among the most discussed catalog peptides in connective-tissue and gastrointestinal preclinical literature — with a large but investigator-concentrated rodent bibliography.
TB-500 commonly refers to a fragment or analog related to thymosin beta-4 actin-binding biology. Catalog naming is inconsistent — full-length Tβ4, fragments, and mislabeled products all appear in commerce.
Semaglutide is a GLP-1 receptor agonist with extensive published human trial literature as an approved drug product. Catalog research peptide labeled semaglutide is a separate RUO material — not interchangeable with pharmaceutical formulations without verified identity and context.
Tirzepatide combines GIP and GLP-1 receptor agonism in a single acylated peptide — a distinct research object from GLP-1–selective molecules like semaglutide, with large published SURPASS and SURMOUNT trial programs.
Retatrutide is a development-stage triple agonist adding glucagon receptor activity to dual incretin pharmacology. Human data are earlier and narrower than for semaglutide or tirzepatide, with active phase 2 literature.
Ipamorelin is a selective growth hormone secretagogue studied for relatively narrow hormonal release profiles compared with first-generation GHRPs. It is frequently paired in research discussions with GHRH analogs such as CJC-1295.
The no-DAC form of CJC-1295 is a shorter-acting GHRH analog than the DAC-modified variant. Research discussions often pair it with ipamorelin or GHRP-class peptides — combination data remain predominantly preclinical.
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) associated with telomerase and pineal-aging research from the Khavinson bioregulator literature. Catalog material is analytically simple but requires batch identity confirmation.
MOTS-c is a 16-residue peptide encoded within mitochondrial 12S rRNA, studied for metabolic regulation and exercise-mimetic effects in rodent models. Endogenous production and exogenous supply are distinct research contexts.
SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide studied in mitochondrial dysfunction, heart failure, and rare disease research programs with published clinical-stage data — distinct from most catalog-only longevity peptides.
GHK-Cu is the copper complex of a naturally occurring tripeptide studied across dermatology, wound-healing, and cosmetic science for decades. It is analytically tractable but frequently sold without adequate identity or copper-content documentation.
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist derived from melanocortin peptide chemistry. It has published phase 3 clinical literature for central sexual-arousal pathways and is FDA-approved as Vyleesi — distinct from catalog RUO material without pharmaceutical documentation.
Selank is a synthetic heptapeptide derived from tuftsin with an added Gly-Pro C-terminal extension. Russian and Western literature describes anxiolytic-like effects in rodent models without classical benzodiazepine sedation, plus immunomodulatory research angles.
Semax is a synthetic heptapeptide analog of the ACTH(4-10) fragment developed in Russian neuropharmacology programs. Western-indexed literature explores neurotrophic gene expression, BDNF-related signaling, and neuroprotection in rodent models.
Tesamorelin is an FDA-approved GHRH analog studied in phase 3 trials for HIV-associated lipodystrophy with excess visceral adipose tissue. Catalog material is a distinct RUO supply chain from pharmaceutical Egrifta.
Community content — not medical advice. Research use only; nothing here is instruction for human use.
We use strictly necessary cookies to run the site (your sign-in session and this choice). With your consent we also use analytics cookies to improve the site. See our Cookie Policy and Privacy Policy.